October 18, 2021
Video
Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.
October 07, 2020
Article
At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.
October 06, 2020
Article
With the number of targets in gastrointestinal cancer growing, particularly KRAS in colorectal cancer and tumor mutational burden across all gastrointestinal tumors, Andrea Cercek, MD, sought to provide an overview of current and emerging targets during the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
October 05, 2020
Article
In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.
October 05, 2020
Article
Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
October 05, 2020
Article
In an interview with Targeted Oncology following ISGIO 2020, Elena Chiorean, MD, oncologist, discussed universal genetic testing at the time of diagnosis for patients with pancreatic cancer, a topic she argued on during an ISGIO medical crossfire. She also explained the challenges with execute germline testing setting.